Print Page  Close Window


Enumeral is discovering and developing novel antibody immunotherapies that help the immune system attack diseased cells. We have a unique ability to extensively interrogate the human immune microenvironment for candidate selection and validation. Our unique capabilities enable us to measure drug effects in a patient-specific manner, providing the basis for developing best-in-class product candidates, based on a fundamental understanding of how immunotherapies work in each patient. We are building a pipeline of immunomodulators for the treatment of cancer and inflammatory diseases and leveraging the breadth of our technology through strategic collaborations.
Stock Quote
ENUM (Common Stock)
ExchangeOTC BB (US Dollar)
Change (%)0.00 (NaN%)
Data as of 02/02/18 4:00 p.m. ET
Upcoming EventsMore >>
There are currently no events scheduled.